Shield Therapeutics announces exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co. Ltd in China.

8 Jan 2020

Shield Therapeutics plc,  announces that it has entered into an exclusive licence agreement for its lead product Feraccru®/Accrufer® (ferric maltol) with Beijing Aosaikang Pharmaceutical Co. Ltd in China, Hong Kong, Macau and Taiwan. For further details click here.

Back to news